Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Depreciation & Amortization (CF) (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $81000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 6.58% to $81000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $329000.0, a 11.15% increase, with the full-year FY2024 number at $308000.0, up 7.32% from a year prior.
  • Depreciation & Amortization (CF) was $81000.0 for Q3 2025 at Orchestra BioMed Holdings, roughly flat from $81000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $84000.0 in Q4 2024 to a low of $48000.0 in Q1 2022.
  • A 4-year average of $70800.0 and a median of $73000.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): surged 47.92% in 2023, then grew 1.37% in 2024.
  • Orchestra BioMed Holdings' Depreciation & Amortization (CF) stood at $70000.0 in 2022, then grew by 2.86% to $72000.0 in 2023, then rose by 16.67% to $84000.0 in 2024, then dropped by 3.57% to $81000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Depreciation & Amortization (CF) are $81000.0 (Q3 2025), $81000.0 (Q2 2025), and $83000.0 (Q1 2025).